AP3M2

Across TCGA pan-cancer cohorts, AP3M2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AP3M2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AP3M2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AP3M2 expression acts as an unfavorable survival marker, although some lineages such as COAD and CCRCC show a favorable association.

HNSC, COAD, and CCRCC are the cancer types where AP3M2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.773	0.924	<.001	92	view →
COAD	DFS	Quartile	II,III,IV	1.000	0.864	.039	24	view →
CCRCC	DFS	Tertile	III,IV	1.000	0.740	.012	17	view →
LSCC	DFS	Tertile	All	0.150	0.952	<.001	14	view →
GBM	OS	Tertile	All	0.247	0.639	.008	7	view →
LUAD	OS	Median	II,III,IV	0.832	0.458	.043	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AP3M2–HNSC (OS)

Open the HNSC breakdown →